| Identification | Back Directory | [Name]
LORGLUMIDE | [CAS]
97964-56-2 | [Synonyms]
cr1409
LORGLUMIDE
IEKOTSCYBBDIJC-UHFFFAOYSA-N
LORGLUMIDE SODIUM SALT (CR 1409) NON-PEP TIDE CCK ANTAG
d,l-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pentanoicacid
4-dichlorobenzoyl)amino)-5-(dipentylamino)-5-oxo-4-(((+-)-pentanoicaci
Pentanoic acid, 4-[(3,4-dichlorobenzoyl)amino]-5-(dipentylamino)-5-oxo-
(±)-4-[(3,4-dichlorobenzoyl)amino]-5-(dipentylamino)-5-oxopentanoic acid sodium salt
CR 1409, (±)-4-[(3,4-Dichlorobenzoyl)amino]-5-(dipentylamino)-5-oxopentanoic acid sodium salt | [Molecular Formula]
C22H32Cl2N2O4 | [MDL Number]
MFCD00079850 | [MOL File]
97964-56-2.mol | [Molecular Weight]
459.41 |
| Chemical Properties | Back Directory | [Boiling point ]
621.4±55.0 °C(Predicted) | [density ]
1.195±0.06 g/cm3(Predicted) | [solubility ]
45% (w/v) aq 2-hydroxypropyl-β-cyclodextrin: >10 mg/mL | [form ]
solid | [pka]
4.47±0.10(Predicted) | [color ]
white |
| Hazard Information | Back Directory | [Uses]
Lorglumide is a specific cholecytokinin receptor antagonist. It is also an intermediate in synthesizing Lorglumide Sodium Salt (L469910), a nonpeptidic antagonist of the CCK A receptor, and minimally effective at the CCK B receptor. It blocks CCK -mediated muscle contraction, pancreatic growth and secretion. | [Definition]
ChEBI: N(2)-(3,4-dichlorobenzoyl)-N,N-dipentyl-alpha-glutamine is a dicarboxylic acid monoamide obtained by formal condensation of the alpha-carboxy group of N-(3,4-dichlorobenzoyl)glutamic acid with the amino group of dipentylamine. It is a glutamic acid derivative, a dicarboxylic acid monoamide, a member of benzamides and a dichlorobenzene. |
|
|